Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020160256 - COMPOSITIONS ET MÉTHODES DE TRAITEMENT OU DE LIMITATION DU DÉVELOPPEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

We claim

1. A method for treating or limiting development of age-related macular degeneration

(AMD), comprising administering to a subject in need thereof an amount effective to treat or limit development of AMD of:

(a) a GPR143 receptor agonist;

(b) melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the GPR143 receptor agonist comprises L-DOPA, an L-DOPA analogue, or a pharmaceutically acceptable salt thereof, including but not limited to L-DOPA pro-drug, an L-DOPA ester, a bile acid conjugate of L-DOPA, a di- or tri-peptide L-DOPA analogue, or an amide L-DOPA analogue.

3. The method of claim 1 or 2, wherein the administering is done in the evening 2 hours or less before the subject goes to bed.

4. The method of claim 1 or 2, wherein the administering is done in the evening 1 hour or less before the subject goes to bed.

5. The method of any one of claims 1-4, wherein the administering is done 2 hours or less before sunset.

6. The method of any one of claims 1 -4, wherein the administering is done 1 hour or less before sunset.

7. The method of any one of claims 1-6, wherein the administering is done once per day.

8. The method of any one of claims 1-7, wherein the administering comprises oral administering.

9. The method of any one of claims 1-7, wherein the administering comprises administering by eye drops.

10. The method of any one of claims 1 -7, wherein the administering comprises intranasal or pulmonary administering.

11. The method of any one of claims 1-10, wherein the method is for treating AMD, and wherein the subject has wet AMD.

12. The method of any one of claims 1-10, wherein the method is for treating AMD, and wherein the subject has dry AMD.

13. The method of any one of claims 1-12, wherein the subject is undergoing anti-vascular endothelial growth factor therapy.

14. The method of any one of claims 1-10, wherein the method is for limiting

development of AMD, and wherein the subject has one or more of drusen deposits, lipofuscin deposits, or pseudodrusen (RPD) deposits.

15. The method of any one of claims 1-14, wherein the method further comprises treating the subject with light therapy the morning following the administering.

16. The method of any one of claims 1-15, further comprising administering to the subject carbidopa, or a pharmaceutically acceptable salt thereof.

17. The method of any one of claims 1-16, comprising administering to a subject in need thereof an amount effective to treat or limit development of AMD of:

(a) L-DOPA, or a pharmaceutically acceptable salt thereof; and

(b) melatonin, or a pharmaceutically acceptable salt thereof

18. A composition comprising:

(a) a GPR143 receptor agonist, including but not limited to L-DOPA, an L-DOPA analogue, or a pharmaceutically acceptable salt thereof;

(b) melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof; and

(c) a pharmaceutically acceptable carrier.

19. The composition of claim 18, wherein the composition comprises L-DOPA or a pharmaceutically acceptable salt thereof.

20. The composition of claim 18, wherein the composition comprises an L-DOPA analogue, or a pharmaceutically acceptable salt thereof.

21. The composition of claim 20, wherein the L-DOPA prodrug comprises an L-DOPA ester, or a pharmaceutically acceptable salt thereof.

22. The composition of claim 20, wherein the L-DOPA prodrug comprises a bile acid conjugate of L-DOPA, or a pharmaceutically acceptable salt thereof.

23. The composition of claim 20, wherein the L-DOPA prodrug comprises a di- or tripeptide L-DOP A analogue, or a pharmaceutically acceptable salt thereof.

24. The composition of claim 20, wherein the L-DOPA prodrug comprises an amide L-DOPA analogue, or a pharmaceutically acceptable salt thereof.

25. The composition of any one of claims 18-24, wherein the composition comprises melatonin, or a pharmaceutically acceptable salt thereof.

26. The composition of any one of claims 18-24, wherein the composition comprises a melatonin analogue, or a pharmaceutically acceptable salt thereof.

27. The composition of claim 26, wherein the melatonin analogue is selected from the group consisting of ramelteon, agomelatine, and tasimelteon.

28. The composition of any one of claims 18-27, further comprising carbidopa, or a pharmaceutically acceptable salt thereof.

29. The composition of claim 18, wherein the composition comprises L-DOPA or a pharmaceutically acceptable salt thereof and melatonin, or a pharmaceutically acceptable salt thereof.

30. The composition of any one of claims 18-29, wherein the composition is formulated as an oral dosage form or as eye drops.

31. The composition of any one of claims 18-29, wherein the composition is formulated intranasal or pulmonary administration.